Modality
Degrader
MOA
BCL-2i
Target
TROP-2
Pathway
Epigenetic
PAH
Development Pipeline
Preclinical
~Nov 2014
→ ~Feb 2016
Phase 1
~May 2016
→ ~Aug 2017
Phase 2
Nov 2017
→ Feb 2025
Phase 2Current
NCT04024080
2,886 pts·PAH
2022-01→2025-02·Completed
NCT05764034
2,761 pts·PAH
2017-11→TBD·Completed
5,647 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-161.1y agoPh3 Readout· PAH
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P2/3
Complet…
P2/3
Complet…
Catalysts
Ph3 Readout
2025-02-16 · 1.1y ago
PAH
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04024080 | Phase 2/3 | PAH | Completed | 2886 | HbA1c |
| NCT05764034 | Phase 2/3 | PAH | Completed | 2761 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D |